Visterra
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
275 2nd Ave Fl 4, Waltham, Massachusetts...Phone Number
(617) 498-1070Website
www.visterrainc.comRevenue
$18.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
3
1
1
About Visterra
Visterra is a biologics research and early-stage clinical development company developing therapies for patients with immune-mediated and other hard-to-treat diseases.Explore more
Visterra Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Visterra your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Visterra launches new products
Funding: Get notified immidiatlly once Visterra has new funding data
Click to see if Visterra had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Visterra
Website visits: Recent activity has been detected on your website
Check out if Visterra is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Visterra recently announced quarterly report
Check if Visterra has recently received funding, and reach out quickly before it becomes old news!
Visterra, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Visterra
Compare insights from companies similar to Visterra, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$97.4M
201-500
Public
$237.2M
1997
CE
Celia EckertSenior Vice President, General Counsel & Corporate Secretary
Company Profile Activity
Activity Insights
Visterra is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Visterra is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Visterra.
Visterra financials insights
Gather financial insights about Visterra, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2008
Other Financing Round
$2M
2012
Private Equity
$34.2M
Series A
$26M
2014
Series B
$30M
2017
Series C
$23.6M
Visterra Tech Stack
A closer look at the technologies used by Visterra
Most Recent Scoops
Promotion
Executive Move
Visterra has announced that Zachary Shriver has been promoted to the role of Chief Executive Officer.
Person-Based
Person-Based
Person-Based
Person-Based
Visterra News & Media
Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeutics for Immune-Mediated and Autoimmune Diseases
CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced a license agreement with Visterra, Inc. to advance Visterra's next-generation biotherapeutic pipeline for...Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) today presented results from a pre-specified interim analysis of the Phase 3 VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of immunoglobulin A nephropathy (IgAN) in adults. Patients treated with sibeprenlimab achieved a 51.2% (P<0.0001) reduction in proteinuria (as measured by 24-hour uPCR [urine protein-to-creatiniOpenFold AI Research Consortium Welcomes New Members Including Bristol Myers Squibb, COGNANO, Lambda, Novo Nordisk, Structure Therapeutics, Tamarind, Unnatural Products, and Visterra
DAVIS, Calif.--(BUSINESS WIRE)--OpenFold continues to expand its collaborative network of academic and industry leaders for the advancement of open-source AI in molecular sciences.Otsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka), today announce positive topline interim data from the ongoing Phase 3 clinical trial of sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgA nephropathy) in adults. Sibeprenlimab is an investigational, anti-APRIL monoclonal antibody (A PRoliferation-Inducing Ligand) that blocks a key initiating step in the immune pathogenic casca
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Visterra
Sign Up For FreeTo access detailed company insights
Visterra is a biologics research and early-stage clinical development company developing therapies for patients with immune-mediated and other hard-to-treat diseases.... Read More
